<DOC>
	<DOCNO>NCT01558284</DOCNO>
	<brief_summary>Placebo control double-blind study 40 patient diarrhea-predominant IBS , 20 get Neu-P11 , 20 get placebo . Neu-P11 , Melatonin receptor- , Serotonin 5-HT- 1A 5-HT- 1D - agonist serotonin 5-HT- 2B - antagonist .</brief_summary>
	<brief_title>The Effect Neu-P11 Symptoms Patients With D-IBS</brief_title>
	<detailed_description>This study aim test possible beneficial effect NEU-P11 patient IBS . The effect symptom rat symptom score . The primary endpoint symptomatic benefit report patient answer simple question : Did symptom improve compare prior clinical trial . Additional secondary endpoint capture sleep quality , change stool texture individual symptom score employ standardized symptom score . The study design 4 week , randomise , placebo-controlled , double blind study 40 patient receive either placebo ( 20 ) NEU-P11 ( 20 ) . In mid four week time Study dose double patient recognize relief D-IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Subjects age 1880 year old 2 . Male female Women childbearing potential must negative pregnancy test screen visit , Day 1 treatment period , use reliable method contraception entire study duration least 3 month study drug intake . Reliable method contraception : oral contraception Double barrier type device ( e.g. , male female condom , diaphragm , contraceptive sponge ) combination spermicide . Intrauterine device combination spermicide . Abstention , rhythm method , contraception partner alone acceptable method contraception . Women childbearing potential define postmenopausal ( i.e. , amenorrhea least 1 year ) , surgically naturally sterile . 3 . Subject IBS confirm Rome III diagnostic criterion 1 . Subject current evidence duodenal ulcer , gastric ulcer , diverticulitis , infectious gastroenteritis . 2 . Subject history inflammatory bowel disease ( e.g . Crohn 's disease , ulcerative colitis , celiac disease ) , GI malignancy , GI obstruction , gastroparesis , carcinoid syndrome , pancreatitis , amyloidosis ileus 3 . Subject candidate GI surgery history GI surgery except appendectomy cholecystectomy . 4 . Subject psychiatric disorder control ( base investigator medical judgment ) ; subject psychosis exclude regardless current therapy . 5 . Subject current recent history ( within 12 month sign informed consent ) drug alcohol abuse . 6 . Subject pregnant lactating 7 . Subject history human immunodeficiency virus ( HIV ) hepatitis ( B C ) 8 . Subject condition circumstance could cause noncompliance treatment visit 9 . Subject active malignancy within last 5 year . 10 . Subject take antipsychotic drug , antispasmodic , antidiarrheal ( e.g . loperamide , lubiprostone bismuth subsalicylate ) , narcotic , prokinetic drug , drug indicate IBS ( e.g Alosetron ) , warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Neu-P11</keyword>
	<keyword>Melatonin</keyword>
	<keyword>D-IBS</keyword>
</DOC>